Alumis Inc.（股票代码：ALMS）今日盘前股价暴涨94.46%，创下显著涨幅，引发市场广泛关注。
这一股价飙升的直接原因是公司宣布其研发的皮肤病药物Envudeucitinib在两项后期临床试验中成功达到主要研究终点。该药物用于治疗中度至重度斑块状银屑病，试验结果显示，约65%的患者在接受24周治疗后皮肤症状改善90%以上，40%以上的患者症状完全消失，疗效显著优于安慰剂及竞争对手安进公司的口服药物Otezla。
分析人士指出，Envudeucitinib通过阻断TYK2蛋白发挥作用，减少导致银屑病的过度免疫反应，其疗效接近最畅销的注射药物，具有成为同类领先TYK2抑制剂的潜力。公司计划于2026年下半年向美国FDA提交上市申请，若获批，将与百时美施贵宝的Sotyktu竞争。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.